Stephen Rubino
Director/Board Member chez VIRACTA THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Stephen Rubino is currently the President, Chief Executive Officer & Director at Sporos Bioventures, Inc., a Director at Sermonix Pharmaceuticals LLC, and an Independent Director at Viracta Therapeutics, Inc. He previously worked as a Director at ILKOS THERAPEUTICS, Inc. from 2017 to 2020, Head-Global Solid Tumor at Schering-Plough Europe SA from 1991 to 2001, Global Head-Business Development at Novartis Pharmaceuticals Corp.
from 2001 to 2017, Chief Business Officer at Celyad Oncology SA from 2020 to 2022, and Chief Business & Strategy Officer at Omega Therapeutics, Inc. from 2018 to 2019.
He holds an MBA from Baruch College and a doctorate from Weill Cornell Medical College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Stephen Rubino
| Sociétés | Poste | Début |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Director/Board Member | 03/03/2021 |
Sermonix Pharmaceuticals LLC
 Sermonix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Sermonix Pharmaceuticals LLC operates as a pharmaceutical company that focuses on the development and commercialization of late-stage women?s health products. It offers lasofoxifene, a selective estrogen receptor modulator for the treatment of vulvovaginal atrophy, as well as treatment and prevention of post-menopausal osteoporosis. The company was founded in 2014 by David Portman and is headquartered in Columbus, OH. | Director/Board Member | - |
Sporos Bioventures, Inc.
 Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Chief Executive Officer | - |
Anciens postes connus de Stephen Rubino
| Sociétés | Poste | Fin |
|---|---|---|
| CELYAD ONCOLOGY SA | Corporate Officer/Principal | 01/04/2022 |
ILKOS THERAPEUTICS, Inc.
 ILKOS THERAPEUTICS, Inc. BiotechnologyHealth Technology ILKOS THERAPEUTICS, Inc. operates as biotechnology firm. It develops drug and clinical solutions for the treatment of venous lower limb ulcers. The company is headquartered in Laval, Canada. | Director/Board Member | 01/02/2020 |
| OMEGA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2019 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/01/2017 |
| Schering-Plough Europe SA | Corporate Officer/Principal | 01/06/2001 |
Formation de Stephen Rubino
| Baruch College | Masters Business Admin |
| Weill Cornell Medical College | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| OMEGA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
| Schering-Plough Europe SA | |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
ILKOS THERAPEUTICS, Inc.
ILKOS THERAPEUTICS, Inc. BiotechnologyHealth Technology ILKOS THERAPEUTICS, Inc. operates as biotechnology firm. It develops drug and clinical solutions for the treatment of venous lower limb ulcers. The company is headquartered in Laval, Canada. | Health Technology |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Health Services |
| Viracta Therapeutics, Inc. | |
Sermonix Pharmaceuticals LLC
Sermonix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Sermonix Pharmaceuticals LLC operates as a pharmaceutical company that focuses on the development and commercialization of late-stage women?s health products. It offers lasofoxifene, a selective estrogen receptor modulator for the treatment of vulvovaginal atrophy, as well as treatment and prevention of post-menopausal osteoporosis. The company was founded in 2014 by David Portman and is headquartered in Columbus, OH. | Health Technology |
